Inhibice signalizace B buněčným receptorem: první cílená léčba u chronické lymfocytární leukemie a dalších B buněčných lymfomů
| Title in English | Inhibition of B Cell Receptor Signaling: A First Targeted Th erapeutic Approach for Chronic Lymphocytic Leukemia and Other B Cell Lymphomas |
|---|---|
| Authors | |
| Year of publication | 2013 |
| Type | Article in Periodical |
| Magazine / Source | Klinická onkologie |
| MU Faculty or unit | |
| Citation | |
| Web | http://www.linkos.cz/files/klinicka-onkologie/178/4240.pdf |
| Field | Oncology and hematology |
| Keywords | BCR signaling; B cell receptor; Btk protein; Syk protein; Lyn protein; PI3K; CAL-101; PCI-32765; R788 |
| Attached files | |
| Description | Chronic lymphocytic leukemia (CLL) is the most frequent, yet by conventional therapy still incurable, leukemia in the Western world. Accumulating evidence of the role of B cell receptor (BCR) pathway in CLL B cell bio logy suggests the possible use of ’BCR inhibitors’ for targeted therapy. Recently published results of clinical trials of three diff erent molecules (fosfamatinib, ibrutinib and GS-1101) targeting BCR-associated kinases (Syk, Btk, PI3K) showed impressive clinical activity in CLL. These fi ndings will likely modify treatment approaches for chronic lymphocytic leukemia and some other B cell lymphomas in the near future. Herein, we review the data on BCR pathway deregulation in malignant CLL B cells, and the results of clinical trials utilizing fosfamatinib, ibrutinib and GS-1101. |
| Related projects: |